KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Accumulated Expenses (2016 - 2019)

Bristol Myers Squibb (BMY) has disclosed Accumulated Expenses for 11 consecutive years, with $81.0 million as the latest value for Q2 2019.

  • On a quarterly basis, Accumulated Expenses fell 98.61% to $81.0 million in Q2 2019 year-over-year; TTM through Jun 2019 was $81.0 million, a 98.61% decrease, with the full-year FY2017 number at $6.0 billion, up 14.1% from a year prior.
  • Accumulated Expenses was $81.0 million for Q2 2019 at Bristol Myers Squibb, down from $5.9 billion in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $6.0 billion in Q4 2017 to a low of $81.0 million in Q2 2019.
  • A 5-year average of $4.3 billion and a median of $4.9 billion in 2016 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 140.7% in 2016, then crashed 98.61% in 2019.
  • Bristol Myers Squibb's Accumulated Expenses stood at $4.7 billion in 2015, then grew by 11.25% to $5.3 billion in 2016, then grew by 14.1% to $6.0 billion in 2017, then fell by 2.68% to $5.9 billion in 2018, then plummeted by 98.62% to $81.0 million in 2019.
  • Per Business Quant, the three most recent readings for BMY's Accumulated Expenses are $81.0 million (Q2 2019), $5.9 billion (Q3 2018), and $5.8 billion (Q2 2018).